# A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers

> **NCT01591837** · PHASE4 · COMPLETED · sponsor: **Seqirus** · enrollment: 120 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** CSL Influenza Vaccine

## Key facts

- **NCT ID:** NCT01591837
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591837, "A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01591837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*